Adoptive immunotherapy for cancer: building on success
暂无分享,去创建一个
[1] P. Lipsky,et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. , 2006, Blood.
[2] C. Klebanoff,et al. Interleukin-2-dependent mechanisms of tolerance and immunity in vivo , 2006, The Journal of Immunology.
[3] S. Rosenberg,et al. Modulation by IL-2 of CD70 and CD27 Expression on CD8+ T Cells: Importance for the Therapeutic Effectiveness of Cell Transfer Immunotherapy1 , 2006, The Journal of Immunology.
[4] S. Rosenberg,et al. Comparison of Common γ-Chain Cytokines, Interleukin-2, Interleukin-7, and Interleukin-15 for the In Vitro Generation of Human Tumor-Reactive T Lymphocytes for Adoptive Cell Transfer Therapy , 2006, Journal of immunotherapy.
[5] Helen Y Wang,et al. Regulatory T cells and Toll-like receptors in tumor immunity. , 2006, Seminars in immunology.
[6] J. Sprent,et al. Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes , 2006, Science.
[7] S. Nutt,et al. Transcriptional repressor Blimp-1 is essential for T cell homeostasis and self-tolerance , 2006, Nature Immunology.
[8] K. Calame,et al. Transcriptional repressor Blimp-1 regulates T cell homeostasis and function , 2006, Nature Immunology.
[9] Thierry Boon,et al. Human T cell responses against melanoma. , 2006, Annual review of immunology.
[10] S. Ziegler,et al. Cutting Edge: Anti-CD25 Monoclonal Antibody Injection Results in the Functional Inactivation, Not Depletion, of CD4+CD25+ T Regulatory Cells1 , 2006, The Journal of Immunology.
[11] S. Rosenberg,et al. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.
[12] M. Cooke,et al. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors , 2006, Nature Medicine.
[13] I. Pastan,et al. Selective Elimination of Human Regulatory T Lymphocytes In Vitro With the Recombinant Immunotoxin LMB-2 , 2006, Journal of immunotherapy.
[14] A. McMichael,et al. Human Naive CD8 T Cells Down-Regulate Expression of the WNT Pathway Transcription Factors Lymphoid Enhancer Binding Factor 1 and Transcription Factor 7 (T Cell Factor-1) following Antigen Encounter In Vitro and In Vivo1 , 2006, The Journal of Immunology.
[15] N. Restifo,et al. The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor. , 2006, Cancer research.
[16] T. Waldmann. Effective cancer therapy through immunomodulation. , 2006, Annual review of medicine.
[17] C. Bordignon,et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. , 2005, Blood.
[18] Gerd Ritter,et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[19] S. Rosenberg,et al. Primary Human T Lymphocytes Engineered with a Codon-Optimized IL-15 Gene Resist Cytokine Withdrawal-Induced Apoptosis and Persist Long-Term in the Absence of Exogenous Cytokine1 , 2005, The Journal of Immunology.
[20] M. Smyth,et al. Supernatural T cells: genetic modification of T cells for cancer therapy , 2005, Nature Reviews Immunology.
[21] E. Gilboa,et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.
[22] S. Rosenberg,et al. Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy1 , 2005, The Journal of Immunology.
[23] B. Fox,et al. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. , 2005, Cancer research.
[24] S. Rosenberg,et al. Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR , 2005, The Journal of Immunology.
[25] S. Rosenberg,et al. Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma , 2005, Journal of immunotherapy.
[26] R. Clark,et al. Human skin cells support thymus-independent T cell development. , 2005, The Journal of clinical investigation.
[27] Andrew J. McMichael,et al. Molecular Signatures Distinguish Human Central Memory from Effector Memory CD8 T Cell Subsets1 , 2005, The Journal of Immunology.
[28] A. Rudensky,et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells , 2005, Nature Immunology.
[29] W. Blackwelder,et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer , 2005, Nature Medicine.
[30] J. Berzofsky,et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells , 2005, Nature Medicine.
[31] S. Rosenberg,et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells , 2005, The Journal of experimental medicine.
[32] L. Kaer,et al. NK cells promote islet allograft tolerance via a perforin-dependent mechanism , 2005, Nature Network Boston.
[33] K. Akashi,et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice , 2005 .
[34] C. Yee,et al. IL-21 Influences the Frequency, Phenotype, and Affinity of the Antigen-Specific CD8 T Cell Response1 , 2005, The Journal of Immunology.
[35] V. Bronte,et al. Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.
[36] T. Waldmann,et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[37] S. Rosenberg,et al. Large-Scale Depletion of CD25+ Regulatory T Cells from Patient Leukapheresis Samples , 2005, Journal of immunotherapy.
[38] D. Speiser,et al. Toward improved immunocompetence of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.
[39] S. Rosenberg,et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.
[40] R. Ahmed,et al. BCL6b mediates the enhanced magnitude of the secondary response of memory CD8+ T lymphocytes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[41] S. Rosenberg,et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. , 2005, Human gene therapy.
[42] S. Rosenberg,et al. Survival, Persistence, and Progressive Differentiation of Adoptively Transferred Tumor-Reactive T Cells Associated with Tumor Regression , 2005, Journal of immunotherapy.
[43] A. Viola,et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers , 2005, The Journal of experimental medicine.
[44] S. Rosenberg,et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] N. Restifo,et al. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. , 2005, Current opinion in immunology.
[46] Richard A. Morgan,et al. Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines , 2005, The Journal of Immunology.
[47] S. Sakaguchi. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.
[48] Yi Li,et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display , 2005, Nature Biotechnology.
[49] S. Rosenberg,et al. Bcl-2 overexpression enhances tumor-specific T-cell survival. , 2005, Cancer research.
[50] D. Speiser,et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. , 2005, The Journal of clinical investigation.
[51] S. Rosenberg,et al. CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells , 2005, The Journal of Immunology.
[52] M. Nishimura,et al. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. , 2005, Cancer research.
[53] C. Klebanoff,et al. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. , 2005, Trends in immunology.
[54] Pedro Romero,et al. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. , 2005, Immunity.
[55] S. Rosenberg,et al. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. , 2005, Blood.
[56] Mitchell Kronenberg,et al. Toward an understanding of NKT cell biology: progress and paradoxes. , 2005, Annual review of immunology.
[57] M. Nishimura,et al. Simultaneous Generation of CD 8 + and CD 4 + Melanoma-Reactive T Cells by Retroviral-Mediated Transfer of a Single T-Cell Receptor , 2005 .
[58] H. Heslop,et al. Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease , 2004, The Journal of experimental medicine.
[59] S. Rosenberg,et al. Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred , 2022 .
[60] C. Klebanoff,et al. Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction1 , 2004, The Journal of Immunology.
[61] Z. Eshhar,et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. , 2004, The Journal of clinical investigation.
[62] F. Finkelman,et al. Prolonged Culture of Vaccine-Primed Lymphocytes Results in Decreased Antitumor Killing and Change in Cytokine Secretion , 2004, Cancer Research.
[63] P. Lansdorp,et al. CD27 Expression Promotes Long-Term Survival of Functional Effector–Memory CD8+Cytotoxic T Lymphocytes in HIV-infected Patients , 2004, The Journal of experimental medicine.
[64] Julian A. Kim,et al. Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells , 2004, Journal of Translational Medicine.
[65] David L. Jaye,et al. MTA3 and the Mi-2/NuRD Complex Regulate Cell Fate during B Lymphocyte Differentiation , 2004, Cell.
[66] S. Rutz,et al. Interleukin‐2 is essential for CD4+CD25+ regulatory T cell function , 2004, European journal of immunology.
[67] S. Rosenberg,et al. Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.
[68] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[69] J. Brayer,et al. Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses , 2004, Cancer Research.
[70] T. Tokuhisa,et al. Bcl6 Acts as an Amplifier for the Generation and Proliferative Capacity of Central Memory CD8+ T Cells1 , 2004, The Journal of Immunology.
[71] P. Kourilsky,et al. Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells1 , 2004, The Journal of Immunology.
[72] T. Schumacher,et al. Tumor Rejection Induced by CD70-mediated Quantitative and Qualitative Effects on Effector CD8+ T Cell Formation , 2004, The Journal of experimental medicine.
[73] A. Mackensen,et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. , 2004, Cancer research.
[74] Thomas M. Schmitt,et al. Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro , 2004, Nature Immunology.
[75] N. Chao,et al. Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. , 2004, Blood.
[76] T. Waldmann,et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[77] D. Zhou,et al. Expression of TNFα by CD3+ and F4/80+ cells following irradiation preconditioning and allogeneic spleen cell transplantation , 2004, Bone Marrow Transplantation.
[78] Tao Dong,et al. Immune Activation and CD8+ T-Cell Differentiation towards Senescence in HIV-1 Infection , 2004, PLoS biology.
[79] S. Rosenberg,et al. Phenotypic and Functional Maturation of Tumor Antigen-Reactive CD8+ T Lymphocytes in Patients Undergoing Multiple Course Peptide Vaccination , 2004, Journal of immunotherapy.
[80] N. Chao,et al. Transfer of allogeneic CD 62 L memory T cells without graft-versus-host disease , 2004 .
[81] S. Korsmeyer,et al. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1 , 2003, Nature.
[82] E. Wherry,et al. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells , 2003, Nature Immunology.
[83] Oreste Acuto,et al. CD28-mediated co-stimulation: a quantitative support for TCR signalling , 2003, Nature Reviews Immunology.
[84] J. Borst,et al. CD27 Promotes Survival of Activated T Cells and Complements CD28 in Generation and Establishment of the Effector T Cell Pool , 2003, The Journal of experimental medicine.
[85] S. Ziegler,et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. , 2003, The Journal of clinical investigation.
[86] M. Schlissel,et al. Regulating antigen-receptor gene assembly , 2003, Nature Reviews Immunology.
[87] J. Blattman,et al. Restoration of CD28 Expression in CD28− CD8+ Memory Effector T Cells Reconstitutes Antigen-induced IL-2 Production , 2003, The Journal of experimental medicine.
[88] Steven A. Rosenberg,et al. Adoptive-cell-transfer therapy for the treatment of patients with cancer , 2003, Nature Reviews Cancer.
[89] S. Rosenberg,et al. Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells , 2003, The Journal of experimental medicine.
[90] L. Naldini,et al. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. , 2003, Blood.
[91] S. Rosenberg,et al. Interleukin-2–Independent Proliferation of Human Melanoma-Reactive T Lymphocytes Transduced With an Exogenous IL-2 Gene Is Stimulation Dependent , 2003, Journal of immunotherapy.
[92] M. Farrar,et al. In Vivo Survival and Homeostatic Proliferation of Natural Killer Cells , 2003, The Journal of experimental medicine.
[93] P. Burkett,et al. Interleukin (IL)-15Rα–deficient Natural Killer Cells Survive in Normal but Not IL-15Rα–deficient Mice , 2003, The Journal of experimental medicine.
[94] E. Field,et al. Total lymphoid irradiation nonmyeloablative preconditioning enriches for IL-4-producing CD4+-TNK cells and skews differentiation of immunocompetent donor CD4+ cells. , 2003, Blood.
[95] Rustom Antia,et al. Lineage relationship and protective immunity of memory CD8 T cell subsets , 2003, Nature Immunology.
[96] S. Ziegler,et al. Induction of FoxP 3 and acquisition of T regulatory activity by stimulated human CD 4 + CD 25 – T cells , 2003 .
[97] F. Sallusto,et al. Opinion-decision making in the immune system: Progressive differentiation and selection of the fittest in the immune response , 2002, Nature Reviews Immunology.
[98] J. Thompson,et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[99] T. Waldmann,et al. IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells , 2002 .
[100] F. Marincola,et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. , 2002, Human gene therapy.
[101] N. Restifo,et al. Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.
[102] M. Raffeld,et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.
[103] J. Lafaille,et al. Interleukin 2 Signaling Is Required for CD4+ Regulatory T Cell Function , 2002, The Journal of experimental medicine.
[104] R. Hodes,et al. Telomeres in T and B cells , 2002, Nature Reviews Immunology.
[105] R. Houghten,et al. Degeneracy of Antigen Recognition as the Molecular Basis for the High Frequency of Naive A2/Melan-A Peptide Multimer+ CD8+ T Cells in Humans , 2002, The Journal of experimental medicine.
[106] M. Hatano,et al. Role for Bcl-6 in the generation and maintenance of memory CD8+ T cells , 2002, Nature Immunology.
[107] J. Sprent,et al. Interleukin (IL)-15 and IL-7 Jointly Regulate Homeostatic Proliferation of Memory Phenotype CD8+ Cells but Are Not Required for Memory Phenotype CD4+ Cells , 2002, The Journal of experimental medicine.
[108] J. Sprent,et al. Overexpression of Interleukin (IL)-7 Leads to IL-15–independent Generation of Memory Phenotype CD8+ T Cells , 2002, The Journal of experimental medicine.
[109] Jiang Zhu,et al. Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. , 2002, The Journal of clinical investigation.
[110] F. Marincola,et al. A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma , 2002, Journal of immunotherapy.
[111] S. Carding,et al. γδ T cells: functional plasticity and heterogeneity , 2002, Nature Reviews Immunology.
[112] D. Richman,et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections , 2002, Nature Medicine.
[113] J. Xiang,et al. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression. , 2002, Cancer research.
[114] H. Schreiber,et al. Immunodominance and tumor escape. , 2002, Seminars in cancer biology.
[115] D. Fearon,et al. Arrested Differentiation, the Self-Renewing Memory Lymphocyte, and Vaccination , 2001, Science.
[116] G. Coukos,et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. , 2001, Cancer research.
[117] Steven A. Rosenberg,et al. Progress in human tumour immunology and immunotherapy , 2001, Nature.
[118] C. Surh,et al. Autologous Regulation of Naive T Cell Homeostasis Within the T Cell Compartment1 , 2001, The Journal of Immunology.
[119] G. Coukos,et al. Regulatory CD 4 1 CD 25 1 T Cells in Tumors from Patients with Early-Stage Non-Small Cell Lung Cancer and Late-Stage Ovarian Cancer 1 , 2001 .
[120] T. Schumacher,et al. CD27 is required for generation and long-term maintenance of T cell immunity , 2000, Nature Immunology.
[121] S. Jameson,et al. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo , 2000, Nature Immunology.
[122] Philippa Marrack,et al. T Cells Compete for Access to Antigen-Bearing Antigen-Presenting Cells , 2000, The Journal of experimental medicine.
[123] T. Waldmann,et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[124] F. Sallusto,et al. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. , 2000, Science.
[125] L. Bogatzki,et al. Naive T Cells Transiently Acquire a Memory-like Phenotype during Homeostasis-Driven Proliferation , 2000, The Journal of experimental medicine.
[126] Jianzhu Chen,et al. Homeostasis-Stimulated Proliferation Drives Naive T Cells to Differentiate Directly into Memory T Cells , 2000, The Journal of experimental medicine.
[127] J W Gratama,et al. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR , 2000, Gene Therapy.
[128] P. Marrack,et al. Control of homeostasis of CD8+ memory T cells by opposing cytokines. , 2000, Science.
[129] P. Dalerba,et al. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[130] M. Atkins,et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. , 2000, The cancer journal from Scientific American.
[131] D. Speiser,et al. High Frequencies of Naive Melan-a/Mart-1–Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals , 1999, The Journal of experimental medicine.
[132] J. Sprent,et al. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. , 1999, Immunity.
[133] D. Pardoll,et al. The role of CD4+ T cell responses in antitumor immunity. , 1998, Current opinion in immunology.
[134] J. Tschopp,et al. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. , 1998, Immunity.
[135] J. Crawford,et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. , 1997, Blood.
[136] D. Hanahan,et al. Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy , 1997, The Journal of experimental medicine.
[137] J. Allison,et al. Co-stimulation in T cell responses. , 1997, Current opinion in immunology.
[138] J. Krauss,et al. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. , 1996, Cancer research.
[139] J. Bluestone,et al. CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.
[140] H. Schreiber,et al. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[141] S. Rosenberg,et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.
[142] John S. Thompson,et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2- incompatible transplanted SCID mice , 1994 .
[143] Brown,et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. , 1994, Blood.
[144] D. Hallahan,et al. Regulation of tumor necrosis factor gene expression by ionizing radiation in human myeloid leukemia cells and peripheral blood monocytes. , 1991, The Journal of clinical investigation.
[145] R. North. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells , 1982, The Journal of experimental medicine.
[146] P. Greenberg,et al. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. , 1980, Journal of immunology.